Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr100.00 SEK
Change Today +1.00 / 1.01%
Volume 24.5K
As of 5:50 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

orexo ab (ORX) Snapshot

Open
kr99.25
Previous Close
kr99.00
Day High
kr100.00
Day Low
kr99.25
52 Week High
01/29/15 - kr149.25
52 Week Low
05/22/14 - kr90.75
Market Cap
3.4B
Average Volume 10 Days
131.4K
EPS TTM
kr-1.60
Shares Outstanding
34.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OREXO AB (ORX)

Related News

No related news articles were found.

orexo ab (ORX) Related Businessweek News

No Related Businessweek News Found

orexo ab (ORX) Details

Orexo AB (publ)., a specialty pharmaceutical company, engages in the development and commercialization of drugs based on patented drug delivery technologies primarily in Sweden and the United States. The company’s product portfolio comprises products on the market, proprietary development programs, and collaboration projects. Its products on the market include Zubsolv sublingual tablets for maintenance treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; Edluar, an active substance zolpidem and for the treatment of short-term insomnia; Diabact UBT, which is used to diagnose the presence of Helicobacter pylori, a bacterium that causes gastric ulcers; and Heliprobe System, which is a doctor’s office test to detect the presence of the gastric ulcer bacterium, Helicobacter pylori. The company’s development programs comprise OX51, a sublingual formulation containing alfentanil, which has completed phase II study for the prevention of acute intense pain associated with care-related diagnostic or therapeutic procedures. Its collaboration projects consist of OX-MPI for the treatment of pain and inflammation through collaboration with Boehringer Ingelheim; OX-NLA for the treatment of allergic and non-allergic rhinitis through a partnership with Meda AB; and OX-CLI for the respiratory tract diseases through collaboration with AstraZeneca. Orexo AB (publ). was founded in 1995 and is headquartered in Uppsala, Sweden.

102 Employees
Last Reported Date: 04/23/15
Founded in 1995

orexo ab (ORX) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr4.1M
Compensation as of Fiscal Year 2014.

orexo ab (ORX) Key Developments

Orexo AB Reports Group and Parent Earnings Results for the First Quarter Ended March 31, 2015

Orexo AB reported group and parent earnings results for the first quarter ended March 31, 2015. For the quarter, the group reported net revenues of SEK 149.0 million compared to SEK 101.9 million reported a year ago. Operating loss was SEK 8.1 million compared to SEK 16.2 million reported a year ago. LBITDA was SEK 5.1 million compared to SEK 13.7 million reported a year ago. Loss before tax was SEK 13.7 million compared to SEK 20.1 million reported a year ago. Loss after tax was SEK 15.5 million or SEK 0.45 per diluted share compared to SEK 21.1 million or SEK 0.66 per diluted share reported a year ago. Cash flow from operations was SEK 6.5 million compared to cash out flow from operations was SEK 99.7 million reported a year ago. Return on equity was a negative of 3% compared to 15% reported a year ago. Net debt was a negative of SEK 206.8 million Gross investments in tangible and intangible fixed assets amounted to SEK 1.0 million compared to SEK 40.6 million reported a year ago. For the quarter, the parent company reported net revenues of SEK 122.5 million compared to SEK 62.9 million reported a year ago. Operating loss was SEK 3.3 million compared to SEK 20.5 million reported a year ago. Loss before tax was SEK 8.7 million compared to SEK 24.3 million reported a year ago. Loss after financial items was SEK 8.8 million compared to SEK 24.3 million reported a year ago. Investments amounted to SEK 1.0 million compared to SEK 40.4 million reported a year ago.

Orexo AB Announces New 24-Week Clinical Study Results

Orexo AB announced data from a 24-week clinical trial assessing the long-term safety and efficacy of Zubsolv® (buprenorphine/naloxone) sublingual tablet (CIII) for the maintenance treatment of opioid dependence. The results establish that Zubsolv is effective, well tolerated and demonstrated a safety profile consistent with the product labeling for sublingual buprenorphine products. In addition less than 1% of the patients exited the study due to treatment failure, which further underpins the medical value of Zubsolv. The results also demonstrated an increase of 15% in employment by the patients participating in the study, which further strengthen the evidence of the value of effective treatment of opioid dependence for the society.

Orexo AB Approves Amendment to the Articles of Association

Orexo AB announced that AGM was held on 15 April 2015, the shareholders approved the amendments to the articles of association.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ORX:SS kr100.00 SEK +1.00

ORX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ORX.
View Industry Companies
 

Industry Analysis

ORX

Industry Average

Valuation ORX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.7x
Price/Book 7.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OREXO AB, please visit www.orexo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.